Introduction {#S0001}
============

Lung squamous cell carcinoma (LSCC) represents the second commonest histological type of non-small cell lung cancer (NSCLC).[@CIT0001] Despite the decrease in the incidence of LSCC in recent years, LSCC accounts for an estimated 30% and 20% of lung cancers in men and women, respectively; approximately 2100,000 new cases are reported worldwide each year.[@CIT0002]--[@CIT0004] LSCC is highly associated with cigarette smoking, and the majority of patients with LSCC are either current or former heavy smokers.[@CIT0005] Therefore, it is not surprising that the genomic mutational profiles of LSCC reflect genomic complexities and high overall mutational loads, which are expected in tobacco carcinogenesis.[@CIT0003]

Epidermal growth factor receptor (*EGFR*) is the most commonly mutated proto-oncogene in non-squamous NSCLC, with typical mutation rates of approximately 10--15% in Caucasians and up to 50% in Asians.[@CIT0006]--[@CIT0009] Targeting EGFR with tyrosine kinase inhibitors (TKIs) has become the cornerstone for the management of advanced non-squamous NSCLCs harboring activating mutations of the *EGFR* gene.

However, genomic alterations in LSCC have not been completely characterized so far. The most frequent somatic mutations and alterations in LSCC have been identified in *TP53, PIK3CA, FGFR1, MET*, and *DDR2*, and none of these biomarkers have been validated as predictive for the particular targeted therapies.[@CIT0003],[@CIT0010] Platinum-based chemotherapy continues to remain the first-line treatment for LSCC owing to the lack of an effective targeted therapy for this disease.[@CIT0011]

Although activating mutations of *EGFR* are uncommon in LSCC, patients with the genetic mutations of this subtype might benefit from EGFR-TKI-targeted therapies with lower side effects and toxicities than those of chemotherapy, thus highlighting the benefit of *EGFR* mutation status identification in patients with LSCC.[@CIT0012]

Cumulative epidemiologic studies have identified several clinicopathological factors such as gender, smoking habits, histology of adenocarcinoma (ADC), and ethnicity that may be associated with a high prevalence of *EGFR* mutations.[@CIT0013]--[@CIT0015] In addition, other tumor imageological characteristics and biological parameters may have a predictive effect on the *EGFR* mutation status in lung ADC.[@CIT0015],[@CIT0016] Unfortunately, the distribution of *EGFR* mutations in LSCC is poorly investigated, and the imageological features related to *EGFR* mutations in LSCC remain unclear. Therefore, in this study, we aimed to analyze the distribution of *EGFR* mutations and the clinical and morphological features of a large population of LSCC patients who underwent therapeutic resection and adjuvant chemotherapy post-surgery. Additionally, we assessed the correlations between clinical and imageological characteristics and the clinical outcome of LSCC patients with *EGFR* mutations.

Methods {#S0002}
=======

Patient Cohort {#S0002-S2001}
--------------

All patients with solitary LSCC who underwent surgical resection at the Shanghai Pulmonary Hospital, affiliated to the Tongji University in China, between February 2013 and December 2017 were examined. A total of 2,322 patients were included in the study. All tumors were classified according to the 2015 World Health Organization classification and staged according to the seventh edition of the TNM system. The TNM stages include three components: primary tumor (T), nodal status for metastasis (N), and metastasis at distant organs (M). Written informed consents were obtained from all the patients, and the study was approved by the Institutional Review Board at the Shanghai Pulmonary Hospital.

Histologic Evaluation And Confirmation {#S0002-S2002}
--------------------------------------

Hematoxylin and eosin (H&E)-stained sections of the tumor were blindly reviewed by three experienced pulmonary pathologists. Immunohistochemical (IHC) staining was performed to exclude mixed and inconspicuous ADC components. The lung tissue sections were deparaffinized three times with xylene and dehydrated through a graded series of ethanol. Endogenous peroxidase activity was quenched with 3% H~2~O~2~ in water for 10 min. Antigen retrieval was performed by heating the slides in 0.1 M sodium citrate (pH 6.0) for 10 min. The sections were then incubated with primary antibodies for 30 min at room temperature. Sections incubated with antibody diluents were used as negative controls. The sections were developed using the Dako EnVision™ visualization system (Dako Cytomation, CA, USA), and the following antibodies were used for IHC staining: ΔNP63 (p40; Calbiochem, Darmstadt, Germany) and cytokeratin 5/6 (CK5/6; Dako).

DNA Extraction And EGFR Mutation Analysis {#S0002-S2003}
-----------------------------------------

The Amplification Refractory Mutation System was used for molecular diagnosis in this study. Between February 2013 and December 2015, genomic DNA was extracted from fresh tissues using the QIAamp DNA Tissue Kit (Qiagen, Hilden, Germany). Mutations in the *EGFR* gene were detected using the Amoy Diagnostics Kit (AmoyDx, Xiamen, China) according to the manufacturer's instructions.[@CIT0017] Between January 2016 and December 2017, DNA was extracted from five serial slices of a 5-μm-thick paraffin section using the DNA Formalin-Fixed Paraffin-Embedded Tissue Kit (Qiagen, Hilden, Germany). *EGFR* mutations were detected using the ACCB Diagnostics Kit (ACCB, Beijing, China) according to the manufacturer's protocol[@CIT0018] The test could detect mutations at a sensitivity of 1% in no less than 5 ng/μL of the DNA sample.

Clinical Assessment {#S0002-S2004}
-------------------

Data regarding patient characteristics at the time of lung cancer diagnosis, including age, sex, smoking history, tumor size, pathological TNM stage, tumor morphology, location, histological type, internal structure, lobulation, margin, shape, spiculation, and texture were collected retrospectively. Recurrence-free survival (RFS) was calculated from the date of surgical resection until the date of confirmed recurrence from any cause. Patients who were alive at the time of analysis were censored at the last known date of follow-up. All patients were followed up for more than 12 months.

Statistical Analysis {#S0002-S2005}
--------------------

We compared the clinicopathological features of *EGFR*-positive patients with those of *EGFR*-negative patients. The *EGFR*-negative patients were consecutively selected from our department between January 2016 and March 2016.[@CIT0019] RFS measurements were obtained from *EGFR*-negative patients who underwent surgery on the same day as *EGFR*-positive patients or at a time that was closest to that of *EGFR*-positive patients. No differences in clinicopathological features were detected between those two non-mutated populations ([Table 1](#T0001){ref-type="table"}). Statistically significant differences in categorical variables between the groups were analyzed using the χ^2^ or Fisher's exact test, as appropriate. RFS was estimated by the Kaplan-Meier method, and the log rank test was used for the univariate analysis. The Cox-proportional hazard model was used for the multivariate analysis. The covariates considered for the multivariate analysis were gender, age, TNM stage, tumor size, and smoking status. Two-sided *P* values of \<0.05 were considered statistically significant. SPSS version 20.0 for Windows (IBM SPSS Statistics, Chicago, IL) was used for the statistical analyses.Table 1The Clinicopathological Characteristics Of Two EGFR-Negative PopulationsFor CFFor RFS*P*Sex0.5 Female67 Male8685Age0.371 ≤602724 \>606570Somking0.486 Non-somker3030 Previous smoker1611 Current smoker4249Drinking0.508 Non-drinking8484 Drinking76TNM stage0.529 I3426 II1720 III & IV2015Tumor size0.4 ≤3cm3738 \>3cm5552Site1 Left4544 Right4748[^2]

Results {#S0003}
=======

Confirmation Of LSCC By H&E Staining And IHC Analysis {#S0003-S2001}
-----------------------------------------------------

The expression of CK5/6 and ΔNP63 (p40) is considered a classical hallmark of LSCC.[@CIT0020]--[@CIT0022] In the present study, three pathologists retrospectively evaluated the H&E- and IHC-stained sections from the 2,322 patients with LSCC. The sections were strongly positive for CK5/6 and ΔNP63 ([[Supplementary Figure](https://www.dovepress.com/get_supplementary_file.php?f=223021.docx)]{.ul}). Based on morphological and IHC data, all included tumors were confirmed to be LSCC.

Distribution Of The EGFR Mutation In LSCC {#S0003-S2002}
-----------------------------------------

*EGFR* gene mutations were detected in 80 of the 2,322 samples (mutation rate, 3.4%). Exon 19 deletions (19-del) and the L858R mutations in exon 21 comprised 48.75% and 32.5% of all *EGFR* mutations, respectively, in LSCC patients. The uncommon *EGFR* mutations observed in the cohort included 5 (6.25%) cases of 20-ins mutations, 3 (3.75%) of T790M mutations, 3 (3.75%) of G719X mutations, and 1 (1.25%) of L861Q mutation. The *dual* T790M and L858R mutations were observed in 2 (2.5%) patients and *dual* G719X and L861Q mutations were found in 1 (1.25%) patient ([Figure 1](#F0001){ref-type="fig"}).Figure 1A comprehensive view of *EGFR* mutations in patients with LSCC (n = 80).

Clinicopathological Characteristics {#S0003-S2003}
-----------------------------------

The clinicopathological characteristics of 80 *EGFR*-positive and 95 *EGFR*-negative cases are listed in [Table 2](#T0002){ref-type="table"}. No differences in age, drinking, TNM stage, tumor size, and site were observed between the two groups. However, the proportion of females was higher in the *EGFR*-positive group than in the *EGFR*-negative group, with statistical significance notwithstanding (*P* = 0.064). The number of patients who never smoked was significantly higher in the *EGFR*-positive group than in the *EGFR*-negative group (*P* = 0.006).Table 2The Clinicopathological Characteristics Of 175 Patients With LSCCEGFR PositiveEGFR Negative*P*Sex0.064 Female147 Male6385Age0.199 ≤602624 \>605470Somking0.006 Non-somker4330 Previous smoker511 Current smoker2649Drinking0.116 Non-drinking6686 Drinking166TNM stage0.533 I3926 II1920 III & IV1915Tumor size0.249 ≤3cm2838 \>3cm5052Site0.169 Left3246 Right4748

Patient Imageological Characteristics {#S0003-S2004}
-------------------------------------

The imageological characteristics of 80 *EGFR*-positive and 95 *EGFR*-negative patients with LSCC, including the internal structure, margin, shape, and presence of lobulation and spiculation, are shown in [Table 3](#T0003){ref-type="table"}. No differences in internal structure, margin, lobulation, and spiculation were detected between the two groups. Irregularly shaped lesions were more common in the *EGFR*-positive group than in the *EGFR*-negative group (*P* = 0.045).Table 3The Imageological Characteristics Of 175 Patients With LSCCEGFR PositiveEGFR Negative*P*Internal structure0.356 Homogeneous1314 Heterogeneous6373Lobulation0.084 Marked6273 None514Margin0.429 Poorly defined6181 Sharp66Shape0.045 Regular312 Irregular6475Spiculation0.129 Marked4955 None1832

The imageological characteristics of *EGFR*-positive and *EGFR*-negative non-smoker patients with LSCC were examined because the majority of patients with *EGFR*-mutated LSCCs were generally non-smokers. As shown in [Table 4](#T0004){ref-type="table"}, no differences in internal structure, margin, shape, and lobulation were detected between the two groups of non-smoker patients. The proportion of marked spiculation was significantly higher in the *EGFR*-positive group than in the *EGFR*-negative group (*P* = 0.043; [Table 4](#T0004){ref-type="table"}; [Figure 2](#F0002){ref-type="fig"}).Table 4The Imageological Characteristics Of Non-Smokers With LSCCEGFR PositiveEGFR Negative*P*Internal structure0.349 Homogeneous2824 Heterogeneous95Lobulation0.363 Marked3425 None34Margin0.092 Poorly defined3329 Sharp40Shape0.221 Regular13 Irregular3626Spiculation0.043 Marked3125 None64 Figure 2Imageological characteristics of non-smoking LSCC patients with (**A**) or without (**B**) *EGFR* mutations.

Analysis Of RFS {#S0003-S2005}
---------------

No significant difference in RFS was identified between the *EGFR*-positive (45.9 months) and *EGFR*-negative (49.5 months) patients. The patients were then stratified into two subgroups based on their need for adjuvant therapy after surgery ([Figure 3](#F0003){ref-type="fig"}). The RFS of *EGFR*-positive patients in both the stage IA group (no specific treatment, 52.5 months *vs*. 47.9 months) and the stage IB-IIIA group (adjuvant therapy, 48.1 months *vs*. 42.4 months) was not significantly different from that in *EGFR*-negative patients.Figure 3Kaplan-Meier curves of recurrence-free survival (RFS) according to the adjuvant therapy status in postoperative patients with LSCC. (**A**) RFS for *EGFR*-mutation patients with stage IA LSCC. (**B**) RFS for *EGFR*-mutation patients with stage IB-IIIA LSCC.

Metastasis Of Patients {#S0003-S2006}
----------------------

Of the 175 patients with LSCC, 127 with follow-up information were included in the analysis; among them, 56 were *EGFR*-positive and 71 had wild-type *EGFR* (WT). The incidence of brain metastases was 1.79% (1/56) in *EGFR*-positive patients and 1.41% (1/71) in *EGFR* WT patients (*P* = 0.038; hazard ratio \[HR\], 1.4). Furthermore, the incidences of bone, lung and multiple-site metastases were 3.57% (2/56) *vs* 1.41% (1/71), 5.36% (3/56) *vs* 1.41% (1/71), and 1.79% (1/56) *vs* 1.41% (1/71) in *EGFR*-positive and *EGFR* WT patients. No significant differences in single-site (brain, bone, and lung) and multiple-site metastases were observed between *EGFR*-positive and *EGFR* WT patients ([Table 5](#T0005){ref-type="table"}).Table 5The Metastatic Site And Number Of Patients With LSCCSingle Site MetastasisMultiple Site Metastasis*P*Brain*P*Bone*P*Lung*P*Others*P*EGFR0.6890.4110.5420.630.689positive1/562/563/563/561/56negative1/711/711/714/711/71

Discussion {#S0004}
==========

The incidence of *EGFR* mutations, imageological features, and clinical outcomes were evaluated in a large cohort of postoperative patients with LSCC in the present study. *EGFR* mutations were detected with increased frequency in females and non-smokers. Moreover, the tumors in patients with *EGFR*-positive mutations were more irregularly shaped and demonstrated marked spiculation compared with those with *EGFR*-negative mutations. Thus, patients with active *EGFR* mutations might benefit from second-generation EGFR-TKIs treatments.[@CIT0023],[@CIT0024]

Consistent with the findings of previous studies,[@CIT0025],[@CIT0026] the *EGFR* mutation rate in patients with LSCC in the current study was 3.4%; however, this value was much lower than that reported in patients with ADC.[@CIT0027] Exon 19-del and L858R mutations in exon 21 of the *EGFR* gene are the two commonest mutations that predict the favorable efficacy of EGFR-TKIs.[@CIT0028] The L858R mutation is reportedly the commonest type of mutation in patients with ADC, whereas exon 19-del is dominant in LSCC. In the present study, exon 19-del and *EGFR* L858R mutations accounted for 48.75% and 32.5% of all *EGFR* mutations, respectively, in patients with LSCC. The mutation rate of the *EGFR* L858R mutation in patients with LSCC was lower than that reported in patients with non-squamous NSCLC.[@CIT0029],[@CIT0030] In contrast, the uncommon *EGFR* mutations observed in the cohort included 5 (6.25%) cases of 20-ins mutations and 3 (3.75%) of T790M mutations. The frequency of uncommon mutations (20-ins and T790M) in LSCC was higher than that in NSCLC, which might partly explain the poor response to EGFR-TKIs.[@CIT0031]

Evaluation of the clinicopathological characteristics of the patients revealed the absence of any association between *EGFR* mutation and the majority of clinicopathological characteristics. However, the proportion of females in the *EGFR*-positive group was higher than that in the *EGFR*-negative group, although statistical significance was not achieved (*P* = 0.064). In addition, *EGFR* mutations were more frequent in non-smokers than in previous smokers or current smokers (*P* = 0.006). Moreover, based on the logistic regression analysis, smoking was negatively correlated (odds ratio \[OR\], 0.68; 95% confidence interval \[CI\], 0.476--0.973; *P* = 0.035) with *EGFR* mutations (data not shown). This is consistent with the clinical characteristics of *EGFR* mutations in ADC and LSCC.[@CIT0013]--[@CIT0015],[@CIT0032]

No differences in tumor metastatic capability and patient outcome were noted; however, the imageological characteristics were different between *EGFR*-positive and *EGFR*-negative LSCC patients. The LSCC lesions were more irregularly shaped in the *EGFR*-positive group than in the *EGFR*-negative group (*P* = 0.045). After subgrouping of the non-smoker LSCC patients into *EGFR*-positive and *EGFR*-negative groups, significantly higher amounts of marked spiculation were detected in the *EGFR*-positive group than in the *EGFR*-negative group (*P* = 0.043). Nonetheless, the logistic regression analysis did not show any correlations between the imageological features and *EGFR* mutations.

Targeting EGFR with TKIs has become the cornerstone for the management of advanced non-squamous NSCLC harboring activating *EGFR* mutations; however, the relevance of EGFR inhibitors in LSCC is poorly defined. The role of erlotinib in the treatment of LSCC, irrespective of the *EGFR* mutation status, has been evaluated in several clinical trials, including the observational PEPiTA study,[@CIT0033] the BR.21 trial,[@CIT0034] the SATURN study,[@CIT0035] the TRUST study,[@CIT0036] the TITAN,[@CIT0037] and the DELTA trial.[@CIT0038] Data from these clinical trials demonstrated that as a maintenance treatment option, the therapeutic effects of erlotinib were similar to those of first- or second-line chemotherapy. Furthermore, the role of afatinib in the treatment of LSCC has been evaluated in several clinical trials.[@CIT0039] Shun Lu and his colleagues conducted a post hoc analysis of the data of patients in the LUX-Lung 8 trial conducted in mainland China.[@CIT0023] Compared with erlotinib, afatinib reduced the risk of disease progression or death in the Chinese subgroup by 30% (HR, = 0.70; 95% CI, 0.38--1.27), thereby indicating that afatinib may be considered as a feasible treatment option for Chinese patients with advanced LSCC following the progression of the disease after platinum-based chemotherapy. Yuri Taniguchi and his colleagues showed that the administration of afatinib to LSCC patients who were selected using the *EGFR* mutation test based on the underlying pulmonary disease and smoking status would likely result in a population with a greater sensitivity to afatinib.[@CIT0039]

This study has several limitations. First, despite the inclusion of large-scale data compared with those of previous studies, the patients belonged to a single center, which can lead to a bias in the selection of patients. Second, this was a retrospective study, and we could not collect any data related to targeted therapy (although afatinib has been shown to be effective for LSCC patients harboring activating *EGFR* mutations); therefore, the efficacy of EGFR-TKIs was not evaluated in this study. The use of molecular testing for early-stage lung cancer patients based on the availability of high-quality resection samples will prove beneficial, particularly for those who present with disease progression, thus providing them with another option during treatment planning.[@CIT0040]

The most important predictors of the presence of *EGFR* mutations in LSCC were female gender, non-smoking habit, irregularly-shaped lesions, and marked spiculation (imageological finding). The administration of EGFR-TKIs to patients with LSCC after screening for *EGFR* mutations on the basis of their clinical and imageological features would likely result in a population with a greater sensitivity to afatinib.
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